Last reviewed · How we verify

metronidazole and doxycycline — Competitive Intelligence Brief

metronidazole and doxycycline (metronidazole and doxycycline) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antibiotic combination. Area: Infectious Disease.

marketed Antibiotic combination Bacterial DNA (metronidazole); bacterial 30S ribosome (doxycycline) Infectious Disease Small molecule Live · refreshed every 30 min

Target snapshot

metronidazole and doxycycline (metronidazole and doxycycline) — Hospital de Clinicas de Porto Alegre. Metronidazole and doxycycline together provide broad-spectrum antimicrobial coverage by disrupting bacterial DNA synthesis and protein production.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
metronidazole and doxycycline TARGET metronidazole and doxycycline Hospital de Clinicas de Porto Alegre marketed Antibiotic combination Bacterial DNA (metronidazole); bacterial 30S ribosome (doxycycline)
Vonoprazan + amoxicillin Vonoprazan + amoxicillin The Third Xiangya Hospital of Central South University marketed Potassium-competitive acid blocker (PCAB) + beta-lactam antibiotic combination H+/K+-ATPase (vonoprazan); bacterial cell wall peptidoglycan (amoxicillin)
loteprednol etabonate/tobramycin opthalmic suspension loteprednol etabonate/tobramycin opthalmic suspension Bausch & Lomb Incorporated marketed Corticosteroid/Aminoglycoside antibiotic combination Glucocorticoid receptor (loteprednol); bacterial ribosome 30S subunit (tobramycin)
PPI-amoxicillin-clarithromycin PPI-amoxicillin-clarithromycin National Taiwan University Hospital marketed Antibiotic combination therapy with acid suppression Helicobacter pylori (bacterial pathogen); PPI targets H+/K+-ATPase; amoxicillin targets bacterial cell wall; clarithromycin targets bacterial ribosome
Acnatac® Gel left face Acnatac® Gel left face GWT-TUD GmbH marketed Topical antibiotic combination Bacterial ribosome (clindamycin); oxidative stress induction (benzoyl peroxide)
Different Antibiotic Combinations Different Antibiotic Combinations Inonu University marketed Antibiotic combinations Multiple bacterial targets including cell wall synthesis, protein synthesis, and DNA replication
Vonoprazan+amoxicillin 7 days Vonoprazan+amoxicillin 7 days Xijing Hospital of Digestive Diseases marketed Potassium-competitive acid blocker + beta-lactam antibiotic combination H+/K+-ATPase (vonoprazan); bacterial cell wall peptidoglycan (amoxicillin)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antibiotic combination class)

  1. Michael E. DeBakey VA Medical Center · 2 drugs in this class
  2. University of South Florida · 2 drugs in this class
  3. Halmstad County Hospital · 1 drug in this class
  4. Hospital General Universitario Elche · 1 drug in this class
  5. Hospital de Clinicas de Porto Alegre · 1 drug in this class
  6. McMaster University · 1 drug in this class
  7. Assistance Publique - Hôpitaux de Paris · 1 drug in this class
  8. Shanghai Jiao Tong University School of Medicine · 1 drug in this class
  9. The Cleveland Clinic · 1 drug in this class
  10. The Forsyth Institute · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). metronidazole and doxycycline — Competitive Intelligence Brief. https://druglandscape.com/ci/metronidazole-and-doxycycline. Accessed 2026-05-18.

Build your own brief

Pick any drug + add comparators: